OmniAb, Inc.

OmniAb, Inc. is a biotechnology company that licenses its discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to enable the discovery of therapeutics. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and target-binding proteins for partners' drug development efforts. Its OmniAb platform uses Biological Intelligence to power the immune systems of proprietary and engineered transgenic animals, generating optimized antibody candidates for human therapeutics. Key animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which are genetically modified to produce antibodies with human sequences. Additionally, OmniAb offers OmniFlic and OmniClic for bispecific antibody discovery, OmniTaur for cow-inspired antibodies, OmnidAb for single-domain antibodies, and OmniDeep, a suite of AI and machine learning tools for therapeutic discovery and optimization.

OmniAb, Inc. is listed on the NasdaqGM exchange under the ticker symbol OABI. The company's stock is traded in United States Dollars (USD). As a publicly traded company on a major US exchange, its financial reporting and share pricing are denominated in USD, which is the standard currency for companies listed in the United States.

OmniAb, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing and licensing advanced antibody discovery technologies for therapeutic development. The company's work involves genetic engineering of animals to produce human-like antibodies, which are then used by partners to create drugs for various diseases. This places OmniAb at the intersection of biotechnology and drug discovery, serving the broader healthcare ecosystem.

OmniAb, Inc. is headquartered in Emeryville, California, United States. The company serves clients in the United States, Europe, Japan, China, and Canada. Its technology is licensed to pharmaceutical and biotech companies, as well as academic institutions, across these regions. OmniAb's global reach allows it to collaborate with partners worldwide in the discovery of antibody-based therapeutics, leveraging its proprietary platforms to address a wide range of disease targets.

OmniAb, Inc. generates revenue by licensing its discovery research technology to pharmaceutical and biotech companies, as well as academic institutions. The company's business model is based on providing access to its OmniAb platform, which includes a suite of transgenic animal technologies (such as OmniRat, OmniChicken, and OmniMouse) and in silico tools like OmniDeep. Partners use these technologies to discover and optimize antibody candidates for human therapeutics. Additionally, OmniAb has an agreement with mAbsolve Ltd. to incorporate its Fc-silencing platform technology into antibodies generated using OmniAb's discovery platform, which may also contribute to revenue through licensing or collaboration fees.